BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Tune Therapeutics
Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine.
